<DOC>
	<DOCNO>NCT00838656</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , gemcitabine , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know treatment regimen may kill tumor cell . PURPOSE : This randomized phase II trial study well give one two chemotherapy regimen contain carboplatin , gemcitabine , paclitaxel work treat patient undergo surgery newly diagnose primary stage IIIC stage IV ovarian cancer , fallopian tube cancer , primary peritoneal cancer .</brief_summary>
	<brief_title>Two Different Schedules Carboplatin , Paclitaxel , Gemcitabine , Surgery Treating Patients With Newly Diagnosed Stage IIIC Stage IV Primary Epithelial Ovarian Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To examine compare feasibility two sequential neoadjuvant regimens patient newly diagnose , stage IIIC-IV ovarian peritoneal carcinoma . - To confirm feasibility extend sequential regimen offer 6+6 course chemotherapy patient present inoperable disease . - To establish feasibility biweekly paclitaxel v without gemcitabine hydrochloride adjuvant phase , carboplatin neoadjuvant induction . OUTLINE : This multicenter study . Patients stratify accord serum albumin ( &lt; 30 g/dL vs 30-35 g/dL v &gt; 35 g/dL ) , FIGO stage ( stage IIIC v stage IV ) , histological grade ( well-differentiated [ grade 1 ] v moderately well-differentiated [ grade 2 ] v poorly differentiate [ grade 3 ] ) . Patients randomize 1 2 treatment arm . - Neoadjuvant therapy : - Arm I : Patients receive carboplatin IV 1 hour gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive carboplatin IV 1 hour day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . In arm , patient disease progression switch adjuvant paclitaxel-based chemotherapy . Patients respond disease switch regimen may undergo debulking surgery investigator 's discretion . - Surgery : After completion 6 course chemotherapy , patient evaluate surgery . Patients questionable operability base clinical radiological criterion re-assessed laparoscopically . Patients judge disease amenable optimal debulking laparotomy recommend debulking surgery . Patients judge disease amenable optimal debulking reconsider surgery receive additional 6 course chemotherapy . Patients disease progression completion 12 course chemotherapy undergo laparotomy clinically press need palliate condition surgery offer prospect achieve result ( e.g. , palliation bowel obstruction ) . - Adjuvant therapy : - Arm I : Patients receive paclitaxel IV 3 hour day 1 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive paclitaxel IV 3 hour gemcitabine hydrochloride IV 30 minute day 1 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Patients complete quality life questionnaire baseline , completion course 6 neoadjuvant therapy , course 7 , end study treatment . After completion study therapy , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinically , radiologically , histologically confirm diagnosis 1 following : Primary epithelial ovarian cancer Primary peritoneal carcinoma Ovarian carcinosarcoma Fallopian tube carcinoma Newly diagnose , stage IIIC/IV disease without ascites None follow histology allow : Mucinous Classic clear cell Micropapillary microacinar borderline tumor without invasive implant Unsuitable primary debulking surgery , define follow : Laparoscopic minor surgicalstaging procedure Supplementary clinical radiological assessment Presenting factor affect suitability successful complete resection necessarily prompt laparoscopic assessment , include follow : CT scan MRI evidence peritoneal carcinomatosis , extensive mesenteric infiltration , diaphragmatic involvement , extensive retroperitoneal involvement , cytologically verify malignant pleural effusion and/or ascites Clinical evidence ascites radiological evidence multisite disease Clinical evidence pelvic infiltration radiological evidence multisite disease FIGO stage IV disease , include cervical/supraclavicular lymphadenopathy , intrahepatic parenchymal metastasis , cytologically confirm malignant pleural effusion No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy ≥ 3 month WBC &gt; 3.0/mm³ Platelet count ≥ 100,000/mm³ ANC ≥ 1,500/mm³ AST ALT &lt; 2.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2.5 time ULN Bilirubin &lt; 1.5 time ULN Estimated glomerular filtration rate ≥ 30 mL/min No diabetic , hypertensive smoker , patient preexist occult neuropathic deficits No poorly control , potentially serious medical condition , include follow : Cerebrovascular event within past 12 month Severe chronic respiratory condition require prior hospitalization Active infection Poorly control seizure Morbid psychiatric condition likely render treatment compliance protocol difficult No malignancy treat chemotherapy radiotherapy except nonmelanoma skin cancer carcinoma situ cervix Prior malignancy diseasefree &gt; 5 year treat chemotherapy allow No reason likely cause inability comply treatment schedule followup Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ovarian carcinosarcoma</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
</DOC>